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EDITORIAL REVIEWS 
Intracoronary Stents: Will They Fulfill Their Promise as an 
Adjunct to Angioplasty?” 
STEPHEN G. ELLIS, MD, ERIC J. TOPOL, MD 
Ann Arbor, Michignn 
Coronary angioplasty as it is now performed has several 
limitations, including abrupt early arterial closure and 
delayed restenosis. To obviate these problems and to en- 
hance the safety of the technique, several intracoronary 
stenting devices have been developed and are under inves- 
tigation. This report reviews the scientific rationale behind 
stenting, the results of stenting in animal models and the 
early results in humans. In early clinical investigation, 
restenosis appears uncommon but abrupt, presumably 
In 1977 Gruentzig et al. (I), expanding on the work of Dotter 
and Judkins (2), performed the first coronary angioplasty in 
humans. Today, this procedure has revolutionized the treat- 
ment of patients with coronary artery disease, and >200,000 
coronary angioplasties are performed annually in the United 
States. That successful angioplasty may provide patients 
with stable or unstable angina 210 years of relief from their 
symptoms has now been established (3), and trials are 
underway to determine whether coronary angioplasty or 
bypass surgery should be performed in most patients with 
multivessel coronary disease. The use of coronary angio- 
plasty has now been successfully extended to patients pre- 
senting with acute myocardial infarction (4), although logis- 
tic and financial considerations suggest that its emergency 
use in this setting be limited to patients who have had 
unsuccessful or who have contraindications to intravenous 
thrombolytic therapy (5). 
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thrombotic, occlusion has been reported despite aggressive 
anticoagulation. As long as the potential for this problem 
remains and the long-term consequences of placing these 
devices into arteries of great functional importance remain 
unknown, stent placement must be undertaken with great 
caution and should be performed under carefully moni- 
tored circumstances with meticulous patient follow-up. 
(J Am Co11 Cardiol1989;13:1425-30) 
Limitations of the Current 
Angioplasty Technique 
Abrupt coronary closure. Coronary angioplasty as it is 
now performed has several limitations. First, major ischemic 
complications develop in about 4% to 5% of elective proce- 
dures (6,7). Although patients at highest risk of complica- 
tions can be identified, abrupt coronary closure occurs to a 
certain extent unpredictably (8,9). The mechanism of abrupt 
closure appears most often to be coronary dissection, often 
with secondary superimposition of thrombus formation and 
coronary spasm (10). Even though the use of prolonged 
balloon inflations, intracoronary thrombolytic agents and 
nitrates can alleviate ischemia and obviate the need for 
emergency bypass surgery in some instances, surgery was 
required in 3.4% of patients in the 1985-1986 National Heart, 
Lung and Blood Institute Registry (7). Even in the best of 
surgical centers, when a patient with ongoing ischemia is 
sent for coronary bypass surgery, there is a 27% likelihood 
of Q wave infarction, and this marker of lost myocardium 
predicts a poor 5 year survival rate (I 1). 
Restenosis. Second, new stenosis at the site dilated 
(restenosis) occurs in 16% to 34% of patients (12,13), and 
may occur in >40% of patients undergoing coronary angio- 
plasty of stenosis located in the proximal anastomosis or 
body of saphenous vein bypass graft, proximal portion of the 
left anterior descending coronary artery, ostium of the right 
coronary artery or points of angulation or total occlusion 
(14-18). Restenosis also occurs more commonly after a 
suboptimal angioplasty result (l3), and seems in most in- 
01989 by the American College of Cardiology 0735.1097/89/%3,50 
1426 ELLIS AND TOPOL JACC Vol. 13, No. 6 
STENTING AFTER CORONARY ANGIOPLASTY May 1989: 1425-30 
Table 1. Characteristics of Coronary Stents Currently Available for Human Investigation 
Expanded Configuration* Composition Deployment Flexible 
Length 
(mm) 
Wallstent 0.08 mm stainless 
steel filaments 
PTCA balloon/ 
self-expanding 
Yes 15 to 23 
Palmaz design 0.015 mm stainless 
steel filaments 
PTCA balloon- 
expandable 
Not 
Gianturco design 0.015 mm stainless PTCA balloon- Yes 20 
steel filaments expandable 
*Full length not shown; tflexible articulated design has recently been approved by the U.S. Food and Drug Administration for investigation. PTCA = 
percutaneous transluminal angioplasty. 
stances to be caused by myointimal proliferation, perhaps 
consequent to growth factors released by platelets adherent 
to the damaged coronary intima or media (19,20). Stenosis 
elasticity may also contribute to restenosis. To date, no 
medical intervention to prevent restenosis has been unequiv- 
ocally successful. 
Old coronary occlusion. Third, angioplasty is severely 
limited in achieving long-term (21) or even short-term suc- 
cess in coronary vessels that have been occluded for >8 to 
20 weeks (18,22). By this time, the occlusion is often too firm 
to cross, and even if the occluded segment can be success- 
fully dilated, restenosis is common (18,21,22). 
Recurrent ischemia after myocardial infarction. A fourth 
major limitation of the technique occurs when it is applied in 
the setting of acute myocardial infarction. Even though 
initial technical success may be achieved in >80% of pa- 
tients (23,24), 15% to 25% will have recurrent ischemia 
before hospital discharge (5,23,25), and a further 19% to 39% 
will have restenosis within 6 months (26.27). In this setting, 
the presence of thrombus even before coronary angioplasty 
is initiated, the sluggish coronary flow due to downstream 
myocardial edema and the further intimal trauma caused by 
the angioplasty balloon all predispose to recurrent thrombus 
formation and ischemia. 
Recently, a number of alternatives or adjuncts to coro- 
nary angioplasty have been developed to overcome one or 
more of these limitations. These include intracoronary 
stents, atherectomy or pulverizing devices and lasers. 
Intracoronary Stents (Table 1) 
As early as 1969, Dotter (28) proposed and placed a 
tubular coiled wire stent graft to prevent the recurrence of 
peripheral artery stenosis after angioplasty. Despite a sev- 
eral year hiatus in implementation of the concept, a variety 
of stent designs are now being evaluated in an attempt to 
circumvent many of the shortcomings of current angioplasty 
techniques. Self-expanding spiral (29), zigzag (30) and wire 
mesh metal stents (31), thermal memory alloy stents (32,33), 
balloon-expandable metal stents (34) and thromboplastic (35) 
and biodegradable stents have been tested experimentally 
and at least four stent designs have been deployed as an 
adjunct to coronary angioplasty in a total of nearly 200 
patients to date. 
The ideal coronary stent and currently available stents. 
What can we expect from this concept and technology? The 
ideal coronary stent would be 1) flexible enough to allow its 
placement, 2) biocompatible with the coronary artery into 
which it is placed and the blood components that must 
repeatedly traverse it, 3) durable or degradable, and 4) easily 
and safely deployed. Once placed into the coronary artery, it 
would lessen the risk of vessel closure by widening the 
lumen, thereby improving blood flow and decreasing blood 
turbulence and by decreasing the area of disrupted arterial 
media exposed to elements predisposing to thrombus forma- 
tion. Furthermore, the radial stress that may mediate medial 
thickness may be reduced, thus potentially leading to medial 
atrophy and a lessened risk of restenosis. 
Currently available stents fall short of this ideal. The four 
stents undergoing investigation for use in human coronary 
arteries (thermal expandable coil, the Medinvent Wallstent 
and the stents developed in large part by Gianturco [301 
and Palmaz et al. [34]) as well as other devices in earlier 
stages of development will be reviewed in relation to this 
ideal. 
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Flexibility. A certain degree of stent flexibility is a pre- 
requisite for its deployment through the curves of the guiding 
catheter and a possibly tortuous artery to the point of 
dilation. However, cyclic stretching appears to augment the 
smooth muscle cell activity that may lead to restenosis and 
thereby be counterproductive (36). A direct comparison of 
degrees of intimal hyperplasia induced by stent placement in 
experimental animals may be misleading because of differ- 
ences in experimental design. However, support for the 
importance of repeated stretching on stent-induced intimal 
hyperplasia comes from a comparison of the 200 to 450 pm 
intimal thicknesses reported after 6 months of implantation 
of the flexible Wallstent and Gianturco coil stents (3.0 to 5.0 
mm devices) (37-39) with the 100 pm thickness reported 
after the use of the rigid Palmaz stent (40) under similar 
conditions. Intimal hyperplasia after use of the Wallstent in 
humans has been documented by analysis of tissue frag- 
ments removed by percutaneous atherectomy (Simpson J. 
personal communication). One potential solution to this 
problem proposed by Schatz et al. (41) would be to construct 
a stent with multiple short articulated segments: preliminary 
work in animal preparations with such a stent is encourag- 
ing, and this stem has recently been approved by the U.S. 
Food and Drug Administration for limited experimental use 
in humans. Studies by Schatz et al. (40) suggest that intimal 
hyperplasia may reach its maximal thickness 8 weeks after 
implantation and then regress, but this possibility needs to 
be confirmed in human studies. 
Biocompatibility. The biocompatibility of a stenting de- 
vice is dependent on its surface chemistry, surface energy 
and surface texture, both at the time of initial implantation 
and after the effects of prolonged exposure to the arterial 
wall and blood elements. Because endothelium cannot be 
grown on bare metal surfaces and requires the presence of a 
thin layer of fibrin and thrombus. limited thrombus forma- 
tion is essential for healing. The brisk anterograde flow 
allowed by stem placement facilitates the dynamic process 
of orderly but limited fibrin deposition. Surface protein 
absorption is highest for the Group 1B elements such as 
silver and copper, as well as the transitional elements such 
as platinum (42) and, thus, these metals are unsuited for use 
in stents. Thrombogenicity appears to be directly related to 
wire thickness and stent porosity (37). 
The Gianturco-Roubin and Palmaz stents now used uti- 
lize 0.015 mm wires, whereas the Wallstent uses consider- 
ably thicker (0.08 mm) filaments. Perhaps as a result. 13 of 43 
animals in one series in which the Wallstent was used 
developed partially or totally occlusive thrombosis (31) 
whereas thrombosis has been much less common after 
deployment of the Palmaz stent (40) and has not been 
reported with the Gianturco stent except in 3.0 mm arteries 
with generally oversized stents (stent/artery ratio > I .2) 
when the animals were not kept on long-term antiplatelet 
medications (38,43-45). The thrombogenicity of stainless 
steel may be reduced by buffing to minimize surface defects, 
and by administering dextran during the implantation to 
minimize attraction of electronegative platelets to the elec- 
tropositive metal (46). Heparin bonding and endothelial cell 
seeding have also been proposed to decrease stent thrombo- 
genicity. Less certain is the thrombogenicity of nitinol, a 
nickel-titanium alloy that “memorizes” its shape after an- 
nealing at >SOo”C, but after cooling can be shaped for 
deployment over a guidewire only to resume its prior shape 
after warming to body temperature (47). 
Durability. Long-term biocompatibility will depend on 
the effects of surface oxidation, fretting corrosion and re- 
peated stretching within the arterial wall (48). Results of 
stent explanation and examination have been reported for 
stents in place for up to 2 years, and angiographic documen- 
tation of patency now extends to 3 years (Palmaz J, personal 
communication), but the truly long-term effects are not 
known. Biodegradable stents are currently under develop- 
ment. 
Safety and ease of deployment. Safe stent deployment 
requires that stents be flexible, radiopaque and expand 
reliably to a predetermined size. The issue of flexibility has 
been discussed. The desirability of minimizing wire thick- 
ness to reduce thrombogenicity has placed the radiopacity of 
available stainless steel stents at or below the limits of 
resolution of most commercially available laboratory sys- 
tems. As a consequence, premature deployment of a stent 
because of slippage off the dilation balloon may initially be 
unnoticed, and precise deployment may be difficult. More 
radiopaque metals such as gold or platinum are expensive 
and potentially thrombogenic. Tantalum stents appear prom- 
ising (49). but biocompatibility testing is incomplete at this 
time (Schatz R, personal communication). Devices that 
cannot be reliably expanded have the added risk of under- 
sizing (stent/artery ratio <1.0) and stent migration or over- 
sizing (stentiartery ratio ~1.2) and added medial trauma. 
Nitinol stents may expand prematurely in the guiding cath- 
eter and prevent deployment. Balloon-expandable stents 
have the advantage of precise expansion to the limits of the 
delivery balloon Finally, the stent expansion ratio (ex- 
panded/compressed) must be ~4: 1 to allow the compressed 
stent to pass freely through the guide catheter, yet be large 
enough once expanded to support the arterial wall. 
Clinical Trials in Coronary Artery Disease 
The Wallstent. Because the behavior of endovascular 
protheses differs slightly in larger arteries and in veins, this 
discussion will focus on preliminary reported results of stent 
placement in coronary arteries. To date, the largest clinical 
experience with stent placement in human coronary arteries 
has been with the Wallstent, although as just noted, its 
preclinical “track record” is not the best. Sigwart (personal 
communication) has implanted over > 100 stents to date and 
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he and his colleagues (5051) have formally reported prelim- 
inary results of implantation to prevent restenosis or treat 
abrupt closure in 56 patients. Patients were treated with 
aspirin (1 g) the day before the procedure; with heparin, 
calcium channel blocking agents and intracoronary uroki- 
nase during the procedure and with aspirin (990 mg), dipyr- 
idamole (225 mg), nifedipine (60 mg) and acenocoumarin 
daily after the procedure. More recently, the doses of aspirin 
and dipyridamole have been reduced to 100 and 400 mg 
daily, respectively, and sulfinpyrazone (400 mg daily) was 
added. Of the 44 patients treated to prevent restenosis, 43 
had a patent stent at the 24 h follow-up angiogram. Thirty- 
eight patients (86%) had a good long-term clinical result, but 
there have been two documented reocclusions, two pre- 
sumed reocclusions, one documented restenosis and four 
late deaths (10 events in six patients). One patient who died 
suddenly at home had not been taking his prescribed medi- 
cations. Of the 12 patients who received a stent to treat acute 
occlusion, none developed a Q wave infarction or died, and 
none of the 6 patients restudied developed restenosis (51). 
Puel et al. (52) reported early stent occlusion in 12 of 33 
patients treated with the same Wallstent device, but their 
anticoagulant regimen was less intensive and their patient 
selection may have been different from that of the Lausanne 
group. Similarly, Bertrand et al. (53) reported early throm- 
botic occlusion in 4 of 14 patients. Late restenosis, as 
opposed to reocclusion, has been reported (50-53) in five 
patients from these Wallstent series, and has been related to 
poor distal run-off or failure to stent the entire length of the 
dilated segment. 
The Gianturco coil stent. Nine patients have had the 
Gianturco coil stent implanted as a bridge to bypass surgery 
in a preliminary study designed to assess the safety and 
efficacy of stent deployment by Roubin et al. at Emory 
University (Roubin G, personal communication). In these 
patients, the stent appeared to function well. In one patient, 
the stent could not be deployed because of inadequate 
balloon inflation. Subsequently, four patients have had this 
stent implanted without later surgery, and, with brief follow- 
up, all have been without complication. 
The Palmaz stent. Schatz and Palmaz (54) have reported 
their initial experience with the Palmaz stent in patients 
treated to prevent restenosis; their report includes our own 
experience. The rigidity of the nonflexible stent has limited 
its deployment to arteries that provide an easy approach to 
the stenosis and to stenoses that are located on straight 
segments of artery. The articulated flexible stent has been 
implanted in countries outside the United States. In the 
updated experience (Schatz R, personal communication), 
stent deployment has been successfully achieved in 18 of 20 
patients, and in the 2 patients with unsuccessful placement, 
there were no acute complications. One patient has had 
protocol-mandated angiography at 6 months and did not 
have restenosis. The remaining patients have had negative 
exercise test results (1 to 6 month follow-up). Each of the 
other stents has been placed in fewer than five patients in the 
United States, and the experience has been even more 
difficult to evaluate. 
Unresolved Issues 
Will stents obviate the need for bypass surgery for acute 
ischemic complications of coronary angioplasty? Cadaver 
studies (55) have confirmed the ability of stents to tack up 
intimal debris and seal off the subintimal space. The initial 
short-term results reported by Sigwart et al. (5 I) and Roubin 
(personal communication) are encouraging and suggest that, 
at least in some patients, closure-related ischemia can be 
eliminated by stent placement. However, in most instances 
to date, the stenosis treated has been proximal and readily 
accessible. Current stents may not be reliably useful in 
tortuous arteries or for distal occlusions and, therefore, 
perhaps offer little advantage over available “bail out” 
catheters (56) unless long-term stent patency can be ex- 
pected. 
Will stents maintain long-term vessel patency? If the prob- 
lem of abrupt vessel closure resulting from obstructive 
thrombus formation can be overcome, stents may be able to 
provide scaffolding for the limited and organized intimal 
proliferation required for long-term vessel patency. Interest- 
ingly, all arterial segments stented >3 months that have been 
analyzed microscopically by Palmaz et al. (46) have shown 
medial atrophy. This may be the consequence of the stent’s 
protecting the media from the effect of the artery’s pulsatile 
flow, as suggested by the often noted attenuation of the 
media in heavily calcified human coronary arteries (57). 
Supportive data of this concept also come from the work of 
Thubriker et al. (58), whose dental acrylic casted arterial 
segments developed much less atherosclerotic change over 
time than did the noncasted segments. If the stent-induced 
reduction of medial stress and consequent medial atrophy 
diminish the likelihood of restenosis and the long-term 
effects of stent “wearing” do not predispose to other prob- 
lems, then intracoronary stenting may well prove to be a 
useful adjunct to balloon angioplasty for the management of 
patients with coronary artery disease. However, as long as 
the problem of abrupt thrombotic occlusion remains and as 
long as the long-term consequences of placing these foreign 
devices into arteries of great functional importance remain 
unknown, stent placement, like other intracoronary device 
development, must be undertaken with great caution and 
performed only under carefully controlled circumstances 
with meticulous patient follow-up. 
Finally, if initial safety and efficacy of stenting and other 
adjunctive device treatments can be demonstrated, a ran- 
domized comparison of their efficacy with that of standard 
balloon angioplasty will be required to assess their proper 
role in the treatment of coronary artery disease. 
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